logo

For the Inventor, By the Inventor

Aachen, Germany

Gruenenthal Gmbh


USPTO Granted Patents = 361

% Expired Patents = 64.3



Forward Citations = 2,761

Loading Chart...
Loading Chart...

343 inventors (with patents filed for the assignee):

goldMedal Bernd Sundermann (79 out of 82 patents)

silverMedal Werner Guenter Englberger (50 out of 58 patents)

bronzeMedal Klaus Schiene (48 out of 56 patents)

4.  Hagen-Heinrich Hennies (38 out of 39 patents)

5.  Babette-Yvonne Koegel (37 out of 40 patents)

6.  Gregor Bahrenberg (36 out of 46 patents)

7.  Stefan Oberboersch (35 out of 35 patents)

8.  Thomas Christoph (34 out of 37 patents)

9.  Ruth Jostock (30 out of 34 patents)

10.  Robert Frank (30 out of 30 patents)

11.  Elmar Josef Friderichs (29 out of 32 patents)

12.  Corinna Sundermann (28 out of 31 patents)

13.  Klaus Linz (27 out of 35 patents)

14.  Hans Schick (26 out of 36 patents)

15.  Melanie Reich (25 out of 34 patents)


Core Competencies:
Tapentadol
Vanilloid Receptor Ligands
Pain Treatment
Pharmaceutical Composition
Substituted Pyrrolidine
Analgesics
Chronic Pain
KCNQ2/3 Modulators
Aqueous Formulation
Transdermal Administration
Tamper-Resistant Dosage

361 patents:

1. 12747240 - Substituted [1,2,4]triazolo[4,3-a]quinoxalines, dosage forms containing them, and methods of using them to treat or prevent pain and/or inflammation (2026-09-29),
2. 12685726 - Sulfoximines as inhibitors of NaV1.8 (2026-07-21),
3. 12540130 - Substituted pyrrolidine amides IV (2026-02-03),
4. 12522586 - Substituted pyrrolidine amines and amides VI (2026-01-13),
5. 12344605 - Substituted pyrrolidine amides II (2025-07-01),
6. 12331034 - Substituted pyrrolidine amides V (2025-06-17),
7. 11547678 - Aqueous pharmaceutical formulation of tapentadol for oral administration (2023-01-10),
8. 11007156 - Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol (2021-05-18),
9. 10898452 - Stable formulation for parenteral administration of Tapentadol (2021-01-26),
10. 10829480 - 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives (2020-11-10),
11. 10793556 - 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives (2020-10-06),
12. 10765848 - Device and formulation for topical treatment of pain affecting the vulvar area of the female human genital organ (2020-09-08),
13. 10632195 - Pharmaceutical device for electric-field assisted administration of Tapentadol and method of administering Tapentadol with same (2020-04-28),
14. 10626106 - Substituted pyrrolidine amides I (2020-04-21),
15. 10471079 - Combination of selected analgesics and COX-II inhibitors (2019-11-12),
Gruenenthal GmbH, headquartered in Aachen, Germany, specializes in the development and manufacturing of innovative pharmaceutical formulations, particularly in the field of pain management. The company focuses on advanced therapeutic solutions, including tapentadol and various vanilloid receptor ligands, aimed at treating chronic pain effectively. Gruenenthal's research encompasses a range of core technology topics, such as pharmaceutical compositions and analgesics, positioning it as a key player in the pharmaceutical industry dedicated to improving patient outcomes.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Gruenenthal Gmbh
361 Patents

#1 in Aachen

#156 in Germany

#2,542 in the World

Aachen, DE
Aachen, Germany

Gruenenthal Gmbh

Forward Citations = 2,761

343 inventors:

goldMedal Bernd Sundermann (79 out of 82 patents)

silverMedal Werner Guenter Englberger (50 out of 58 patents)

bronzeMedal Klaus Schiene (48 out of 56 patents)

4.  Hagen-Heinrich Hennies (38 out of 39 patents)

5.  Babette-Yvonne Koegel (37 out of 40 patents)

Please report any incorrect information to [email protected]
Loading…